1. The TSP1-CD47-SIRPα interactome: an immune triangle for the checkpoint era

   • Enrique Montero
   • Jeffrey S. Isenberg

   Review Open access 22 May 2023 Pages: 2879 - 2888

   

2. A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma

   • Hong-My Nguyen
   • Mariam Oladejo
   • Laurence M. Wood

   Research 23 December 2022 Pages: 2889 - 2903

   

3. Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers

   • Jordi Pfeifer Serrahima
   • Congcong Zhang
   • Winfried S. Wels

   Research Open access 23 January 2023 Pages: 2905 - 2918

   

4. Therapeutic potential of FLT4-targeting peptide in acute myeloid leukemia

   • Ji Yoon Lee
   • Soojin Park
   • Hee-Je Kim

   Research 10 February 2023 Pages: 2919 - 2925

   

5. Murine regulatory T cells utilize granzyme B to promote tumor metastasis

   • Ellis Tibbs
   • Rakhee Rathnam Kalari Kandy
   • Xuefang Cao

   Research 24 February 2023 Pages: 2927 - 2937

   

6. A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model

   • Joshua F. Meckler
   • Daniel J. Levis
   • Joseph M. Tuscano

   Research Open access 29 May 2023 Pages: 2939 - 2948

   

7. Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study

   • Chengpei Zhu
   • Hu Li
   • Haitao Zhao

   Research Open access 29 May 2023 Pages: 2949 - 2960

   

8. Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study

   • Matteo Santoni
   • Zin W. Myint
   • Camillo Porta

   Research 29 May 2023 Pages: 2961 - 2970

   

9. Spatiotemporal commonality of the TCR repertoire in a T-cell memory murine model and in metastatic human colorectal cancer

   • Mizuki Haraguchi
   • Kazuma Kiyotani
   • Ryohei Katayama

   Research 04 June 2023 Pages: 2971 - 2989

   

10. Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003)

    • Yuankai Shi
    • Jie Cui
    • Wenduo He

    Research 08 June 2023 Pages: 2991 - 3002

    

11. NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model

    • Hampartsoum B. Barsoumian
    • Kewen He
    • James W. Welsh

    Research Open access 08 June 2023 Pages: 3003 - 3012

    

12. Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer

    • Colt A. Egelston
    • Weihua Guo
    • Yuan Yuan

    Research Open access 09 June 2023 Pages: 3013 - 3027

    

13. Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents

    • Claire Battin
    • Annika De Sousa Linhares
    • Peter Steinberger

    Research Open access 13 June 2023 Pages: 3029 - 3043

    

14. IL-36α inhibits melanoma by inducing pro-inflammatory polarization of macrophages

    • Xinyi Lou
    • Shixin Duan
    • Feng Qian

    Research 15 June 2023 Pages: 3045 - 3061

    

15. Characterization of human Fc alpha receptor transgenic mice: comparison of CD89 expression and antibody-dependent tumor killing between mouse strains

    • Marjolein C. Stip
    • J. H. Marco Jansen
    • Jeanette H. W. Leusen

    Research Open access 20 June 2023 Pages: 3063 - 3077

    

16. TGF-β1 mediates tumor immunosuppression aggravating at the late stage post-high-light-dose photodynamic therapy

    • Lingfei Han
    • Xiaoxian Huang
    • Wenyuan Liu

    Research 23 June 2023 Pages: 3079 - 3095

    

17. The RIG-I agonist M8 triggers cell death and natural killer cell activation in human papillomavirus-associated cancer and potentiates cisplatin cytotoxicity

    • Carlo Girone
    • Federica Calati
    • Marisa Gariglio

    Research Open access 25 June 2023 Pages: 3097 - 3110

    

18. Unbiased chemokine receptor screening reveals similar efficacy of lymph node- and tumor-targeted T cell immunotherapy

    • Ludwig O. Pachmayr
    • Anton Muehlbauer
    • Simon Grassmann

    Brief Report Open access 10 June 2023 Pages: 3111 - 3124

    

19. Tumor immunology meets oncology (TIMO) XVI, July 07–09 2022 in Halle/Saale, Germany

    • Barbara Seliger

    Meeting Report Open access 22 June 2023 Pages: 3125 - 3132

20. Considerations regarding the tumor-suppressor role of naringenin as a novel agent for the treatment of oral squamous cell carcinoma

    • Chen-xi Li
    • Zhong-cheng Gong
    • Xiao-rong Tan

    Correspondence 06 May 2023 Pages: 3133 - 3134